R&D
We will make headway into the global market beyond the domestic market by gathering the ability of JW Group.
Research Policy
Based on the long history and know-how in treatment and medicine field, the JW Holdings constantly researching and developing innovative new medicine. We are targeting the diseases with high demand for medical unmet
needs, concentrating on the development of innovative new medicines using the JW’s unique technology, and conducting research activities in line with global trends through open innovation.
JW Pharmaceutical has been focusing on the development of innovative new medicines with its key technologies as cancer stem cells, regenerative medicine, and immune cancer medicines based on our long-established base technology.
-
- Pepetidomimetic chemical library
- WNT modulator for anticancer and tissue regeneration
- Structure-based drug discovery
- Onco-panel assay and data base
- High-throughput screening (HTS) system
- Epigenetic drug discovery
-
- Controlled Release (SMEDDS, Multi-layered Coating)
- Fixed-Dose Combination
- Formulation Change
-
- Process Development of NCE (Salt Selection, Polymorphism)
- High Potency Drug (Peptide, Steroid)
- High Value-added New Technology (High-quality Purification Technology, Continuous Flow Reaction)